Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The new formulation of TETA 4HCl will be administered once a day. Each film-coated tablet is scored to enable halving, if required. Randomized participants are planned to receive TETA 4HCl for the 48-week post-randomization period.”In the company’s words, NCT07465718 on ClinicalTrials.gov
- Tested for
- Wilson's Disease
- Main trialPhase 3
- “The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enrolling children aged 8 years and older weighing at least 55 lb (25 kg) and adults with a recent diagnosis of WD. People recently diagnosed with WD, may be eligible for the study if they have either not started copper chelating treatment (such as DPA or trientine) or have been taking zinc salts for less than 28 days.…”In the company’s words, NCT07465718 on ClinicalTrials.gov
- Other names
- trientine tetrahydrochloride
Other drugs for Wilson's Disease
Coming up1
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2028 | Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. | |
| Phase 3Completed | 19 Aug 2020 | Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease | |
| Phase 1Completed | 8 Feb 2024 | Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026